Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Garin E, et al. Among authors: terroir cassou mounat m. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. Lancet Gastroenterol Hepatol. 2021. PMID: 33166497 Free article. Clinical Trial.
Diagnostic imaging of salivary gland cancers: REFCOR recommendations by the formal consensus method.
Varoquaux A, Fakhry N, Baujat B, Verillaud B, Jegoux F, Barry B, Chabrillac E, Vergez S, Terroir-Cassou-Mounat M. Varoquaux A, et al. Among authors: terroir cassou mounat m. Eur Ann Otorhinolaryngol Head Neck Dis. 2024 Jan;141(1):27-31. doi: 10.1016/j.anorl.2023.11.007. Epub 2023 Nov 29. Eur Ann Otorhinolaryngol Head Neck Dis. 2024. PMID: 38036312 Review.
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. Leboulleux S, et al. Among authors: terroir cassou mounat m. Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. Thyroid. 2023. PMID: 37350119 Clinical Trial. No abstract available.
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Among authors: terroir cassou mounat m. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Free article. Clinical Trial.
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.
Hartl DM, Guerlain J, Breuskin I, Hadoux J, Baudin E, Al Ghuzlan A, Terroir-Cassou-Mounat M, Lamartina L, Leboulleux S. Hartl DM, et al. Among authors: terroir cassou mounat m. Cancers (Basel). 2020 Nov 6;12(11):3282. doi: 10.3390/cancers12113282. Cancers (Basel). 2020. PMID: 33171949 Free PMC article. Review.
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.
Assi T, Danu A, Mateus C, Robert C, Michot JM, Ibrahim T, Lazarovici J, Ghez D, Rossignol J, Dartigues P, Terroir-Cassou-Mounat M, Ribrag V. Assi T, et al. Among authors: terroir cassou mounat m. Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169. Immunotherapy. 2019. PMID: 30943861
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.
Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, De Botton S. Willekens C, et al. Among authors: terroir cassou mounat m. Leukemia. 2018 Sep;32(9):2008-2081. doi: 10.1038/s41375-018-0056-6. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29479068 No abstract available.